drugset / Trial / NCT03326063
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The overall aim of the study is to determine the efficacy of oral ifetroban, a novel antagonist of T prostanoid (TP) receptors, as a treatment for patients with aspirin-exacerbated respiratory disease (AERD).
Timeline
- Start
- 2018-04-26
- Primary completion
- 2022-03-30
- Completion
- 2023-04-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Ifetroban | Small molecule | 200 mg | Oral |